PURPOSE: Targeted inhibition of EGFR with the mAbs cetuximab or panitumumab is a valuable treatment for RAS wild-type colorectal cancers. The efficacy of EGFR blockade is limited by the emergence of acquired resistance often attributed to secondary KRAS mutations. Remarkably, tumor biopsies from resistant patients show that only a fraction of the resilient cells carry KRAS mutations. We hypothesized that a paracrine cross-talk driven by the resistant subpopulation may provide in trans protection of surrounding sensitive cells. EXPERIMENTAL DESIGN: Conditioned medium assays and three-dimensional cocultures were used to assess paracrine networks between cetuximab-sensitive and -resistant cells. Production of EGFR ligands by cells sensitive to cetuximab and panitumumab was measured. The ability of recombinant EGFR ligands to protect sensitive cells from cetuximab was assessed. Biochemical activation of the EGFR signaling pathway was measured by Western blotting. RESULTS: Colorectal cancer cells sensitive to EGFR blockade can successfully grow despite cetuximab treatment when in the company of their resistant derivatives. Media conditioned by resistant cells protect sensitive parental cells from cetuximab. EGFR blockade triggers increased secretion of TGFα and amphiregulin. Increased secretion of ligands by resistant cells can sustain EGFR/ERK signaling in sensitive cells. CONCLUSIONS: Colorectal cancer cells that develop resistance to cetuximab and panitumumab secrete TGFα and amphiregulin, which protect the surrounding cells from EGFR blockade. This paracrine protective mechanism might be therapeutically exploitable.

TGF-α and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells.

MISALE, SANDRA;DI NICOLANTONIO, Federica;BARDELLI, Alberto
2014

Abstract

PURPOSE: Targeted inhibition of EGFR with the mAbs cetuximab or panitumumab is a valuable treatment for RAS wild-type colorectal cancers. The efficacy of EGFR blockade is limited by the emergence of acquired resistance often attributed to secondary KRAS mutations. Remarkably, tumor biopsies from resistant patients show that only a fraction of the resilient cells carry KRAS mutations. We hypothesized that a paracrine cross-talk driven by the resistant subpopulation may provide in trans protection of surrounding sensitive cells. EXPERIMENTAL DESIGN: Conditioned medium assays and three-dimensional cocultures were used to assess paracrine networks between cetuximab-sensitive and -resistant cells. Production of EGFR ligands by cells sensitive to cetuximab and panitumumab was measured. The ability of recombinant EGFR ligands to protect sensitive cells from cetuximab was assessed. Biochemical activation of the EGFR signaling pathway was measured by Western blotting. RESULTS: Colorectal cancer cells sensitive to EGFR blockade can successfully grow despite cetuximab treatment when in the company of their resistant derivatives. Media conditioned by resistant cells protect sensitive parental cells from cetuximab. EGFR blockade triggers increased secretion of TGFα and amphiregulin. Increased secretion of ligands by resistant cells can sustain EGFR/ERK signaling in sensitive cells. CONCLUSIONS: Colorectal cancer cells that develop resistance to cetuximab and panitumumab secrete TGFα and amphiregulin, which protect the surrounding cells from EGFR blockade. This paracrine protective mechanism might be therapeutically exploitable.
20
24
6429
6438
http://clincancerres.aacrjournals.org/content/20/24/6429.long
CANCER; EGFR; Epidermal Growth Factor Receptor (EGFR); TGF-alpha; amphiregulin; paracrine; acquired resistance; cetuximab; kras mutations; cancer evolution; Targeted therapy; Targeted Therapies
Hobor S;Van Emburgh BO;Crowley E;Misale S;Di Nicolantonio F;Bardelli A
File in questo prodotto:
File Dimensione Formato  
POST_2014_Hobor_CCR_4aperto.pdf

Accesso aperto con embargo fino al 31/12/2015

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 1.61 MB
Formato Adobe PDF
1.61 MB Adobe PDF Visualizza/Apri
2014_Hobor_ClinCanRes_Article&SI_Editorial.pdf

Accesso riservato

Descrizione: Articolo principale (PDF Editoriale) e dati supplementari
Tipo di file: PDF EDITORIALE
Dimensione 2.29 MB
Formato Adobe PDF
2.29 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/153388
Citazioni
  • ???jsp.display-item.citation.pmc??? 41
  • Scopus 78
  • ???jsp.display-item.citation.isi??? 72
social impact